GSK Offers a Window Into Attempts at Biotech-like R&D
This article was originally published in The Pink Sheet Daily
Executive Summary
During a nearly two-hour R&D seminar, executives at GlaxoSmithKline PLC described the company's evolving strategy, detailing the organization's goals, capital allocation, and productivity performance, and providing a glimpse into the ongoing work within six of its 40 biotech-like discovery performance units.
You may also be interested in...
GSK R&D President Patrick Vallance On Increasing R&D Productivity: An Interview With PharmAsia News (Part 2 of 2)
An R&D model aimed at bringing the pressure and promise of startups to life within GlaxoSmithKline PLC continues to be tweaked, according to Patrick Vallance, president of pharmaceuticals R&D. He sat down with PharmAsia News during a recent visit to Singapore to give an overview of the company’s strategy.
GSK R&D President Patrick Vallance On Increasing R&D Productivity: An Interview With PharmAsia News (Part 1 of 2)
An R&D model aimed at bringing the pressure and promise of startups to life within GlaxoSmithKline PLC continues to be tweaked, according to Patrick Vallance, president of pharmaceuticals R&D. He sat down with PharmAsia News during a recent visit to Singapore to give an overview of the company’s strategy.
How GSK Is Driving Early Stage Research In Its DPUs
Most of GlaxoSmithKline's early stage research organizations, discovery performance units, survive a three-year review cycle, with co-localization, monetary incentives and career support leading a change of culture.